Patents by Inventor Anne C. Voss
Anne C. Voss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10064835Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.Type: GrantFiled: January 10, 2013Date of Patent: September 4, 2018Assignee: ABBOTT LABORATORIESInventors: Jeffrey L. Nelson, Anne C. Voss, Maria G. Baggs, Charles L. Paule, Refaat A. Hegazi, Fabrizis Suarez, Gary Fanjiang
-
Publication number: 20150133548Abstract: Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.Type: ApplicationFiled: January 10, 2013Publication date: May 14, 2015Applicant: ABBOTT LABORATORIESInventors: Jeffrey L. Nelson, Anne C. Voss, Maria G. Baggs, Charles L. Paule, Refaat A. Hegazi, Fabrizis Suarez, Gary Fanjiang
-
Publication number: 20150119339Abstract: A method of care is described that includes administering an effective amount of ?-hydroxy-?-methylbutyrate (HMB) to an adult or elderly patient to decrease the risk of an adverse health event during or subsequent to hospitalization of the patient.Type: ApplicationFiled: June 10, 2013Publication date: April 30, 2015Applicant: ABBOTT LABORATORIESInventors: Menghua Luo, Jeffrey L. Nelson, Anne C. Voss, Owen J. Kelly, Geraldine E. Baggs, Min Tian, Jamie Partridge
-
Patent number: 8785495Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8785496Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 22, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778993Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8778994Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: July 15, 2014Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Patent number: 8609725Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: January 11, 2012Date of Patent: December 17, 2013Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20130011498Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: January 10, 2013Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120196829Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: August 2, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189714Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189717Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120189716Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189715Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120177752Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 12, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Patent number: 8217077Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: GrantFiled: December 29, 2004Date of Patent: July 10, 2012Assignee: Abbott LaboratoriesInventors: Jeffrey H. Baxter, Pradip Mukerji, Anne C. Voss, Michael J. Tisdale